Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

por Ruppe, Mary D., Zhang, Xiaoping, Imel, Erik A., Weber, Thomas J., Klausner, Mark A., Ito, Takahiro, Vergeire, Maria, Humphrey, Jeffrey S., Glorieux, Francis H., Portale, Anthony A., Insogna, Karl, Peacock, Munro, Carpenter, Thomas O.
Publicado 2016

Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia...

por Zhang, Xiaoping, Imel, Erik A., Ruppe, Mary D., Weber, Thomas J., Klausner, Mark A., Ito, Takahiro, Vergeire, Maria, Humphrey, Jeffrey, Glorieux, Francis H., Portale, Anthony A., Insogna, Karl, Carpenter, Thomas O., Peacock, Munro
Publicado 2015

Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

por Phillips, Adrienne A., Fields, Paul A., Hermine, Olivier, Ramos, Juan C., Beltran, Brady E., Pereira, Juliana, Wandroo, Farooq, Feldman, Tatyana, Taylor, Graham P., Sawas, Ahmed, Humphrey, Jeffrey, Kurman, Michael, Moriya, Junji, Dwyer, Karen, Leoni, Mollie, Conlon, Kevin, Cook, Lucy, Gonsky, Jason, Horwitz, Steven M.
Publicado 2019